Ignite Creation Date:
2025-12-24 @ 6:32 PM
Ignite Modification Date:
2026-01-05 @ 5:17 AM
Study NCT ID:
NCT06467357
Status:
RECRUITING
Last Update Posted:
2025-10-27
First Post:
2024-05-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-08-12
Start Date Type:
ACTUAL
Primary Completion Date:
2028-06-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-05-16
Completion Date Type:
ESTIMATED
First Submit Date:
2024-05-21
First Submit QC Date:
None
Study First Post Date:
2024-06-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-24
Last Update Post Date:
2025-10-27
Last Update Post Date Type:
ESTIMATED